Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.47 |
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.46 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.41 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351964 | 0.98 | ALDH1A1 (0.50) | ALDH1A1HSD17B10CYP1A2LMNACYP3A4 | |
| Hydrochloric Acid SCHEMBL2117780 | 0.82 | KDM4E (0.46) | ALDH1A1CYP1A2LMNACYP3A4MAOA | |
| SCHEMBL28145775 | 0.82 | ALDH1A1 (0.55) | ALDH1A1HSD17B10CYP1A2LMNACYP3A4 | |
| SCHEMBL29659326 | 0.80 | PTGER4 (0.44) | ALDH1A1HSD17B10CYP1A2LMNACYP3A4 | |
| SCHEMBL1149707 | 0.80 | KDM4E (0.47) | ALDH1A1CYP1A2LMNACYP3A4MAOA | |
| SCHEMBL15090763 | 0.79 | KDM4E (0.46) | ALDH1A1CYP1A2LMNACYP3A4MAOA | |
| SCHEMBL2069470 | 0.79 | KMT2A (0.56) | ALDH1A1HSD17B10CYP1A2LMNAKDM4E | |
| SCHEMBL16236949 | 0.79 | KDM4E (0.46) | ALDH1A1CYP1A2LMNAKDM4EGAA | |
| SCHEMBL6778868 | 0.79 | CA12 (0.52) | ALDH1A1CYP1A2KDM4EGAAHPGD | |
| SCHEMBL27969448 | 0.78 | ALDH1A1 (0.46) | ALDH1A1HSD17B10KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569489-B2 | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase | ASTRAZENECA AB (SE) | 2026-03-10 | — | — | US | disclosed |
| EP-4624473-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| EP-4573096-A1 | INHIBITORS OF MYELOPEROXIDASE | Astrazeneca AB (SE) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025107036-A1 | DUAL INHIBITORS OF AMINE OXIDASES AND PEROXIDASES, AND USES THEREOF | SYNTARA LIMITED (AU) | 2025-05-30 | — | — | WO | disclosed |
| CN-119894896-A | Inhibitors of green peroxidase | 阿斯利康(瑞典)有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119768406-A | Process for the preparation of substituted pyrrolopyrimidines and intermediates | 阿斯利康(瑞典)有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119264137-A | Crystal form A of compound A and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240335446-A1 | 1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE | ASTRAZENECA AB (SE) | 2024-10-10 | — | — | US | disclosed |
| WO-2024120457-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2024-06-13 | — | — | WO | disclosed |
| US-20240166642-A1 | INHIBITORS OF MYELOPEROXIDASE | ASTRAZENECA AB (SE) | 2024-05-23 | — | — | US | disclosed |
| EP-1910367-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007142577-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVE AS MYELOPEROXIDASE INHIBITOR | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007115999-A1 | 2, 4-DIAMINOPYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| EP-1824855-A1 | NOVEL PYRROLO [3, 2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-08-29 | — | — | EP | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2007012972-A2 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2007-02-01 | — | — | WO | disclosed |
| EP-1746097-A1 | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | Aventis Pharma S.A. (FR) | 2007-01-24 | — | — | EP | disclosed |
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006062465-A1 | NOVEL PYRROLO [3, 2-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335446-A1 | 1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE | MPO, GPX1, TH | MAOA 113/4885GAA 241/4885CA2 1821/4885 |
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, MMP10 | MAOA 373/4885GAA 287/4885CA2 204/4885 |
| US-20240166642-A1 | INHIBITORS OF MYELOPEROXIDASE | MPO, XDH, EPX | MAOA 41/4885GAA 269/4885CA2 1274/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | MAOA 337/4885GAA 352/4885CA2 196/4885 |
| US-12569489-B2 | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase | MPO, EPX, LPO | MAOA 258/4885GAA 745/4885CA2 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.